Haemophilia specialist nurses’ perceptions of haemophilia B
Article Category: Clinical Practice
Publié en ligne: 14 oct. 2021
Pages: 119 - 127
© 2021 Steve Chaplin et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Experience of use of factor IX products
PRODUCT |
N |
% |
Standard half-life |
Nonacog alfa |
Benefix [31] |
47 |
80% |
Nonacog gamma |
Rixubis [32] |
11 |
19% |
Extended half-life |
Albutrepenonacog alfa |
Idelvion [9] |
22 |
37% |
Eftrenonacog alfa |
Alprolix [8] |
36 |
61% |
Nonacog beta pegol |
Refixia/Rebinyn [10] |
13 |
22% |
Other |
|
17 |
29% |